Literature DB >> 23580319

The pharmacological approach to the elderly COPD patient.

Timothy E Albertson1, Michael Schivo, Amir A Zeki, Samuel Louie, Mark E Sutter, Mark Avdalovic, Andrew L Chan.   

Abstract

The elderly patient (65 years and older) with chronic obstructive pulmonary disease (COPD) can be a challenge to the clinician. This begins with the correct and early diagnosis, the assessment of disease severity, recognizing complicating comorbidities, determining the burden of symptoms, and monitoring the frequency of acute exacerbations. Comprehensive management of COPD in the elderly patient should improve health-related quality of life, lung function, reduce exacerbations, and promote patient compliance with treatment plans. Only smoking cessation and oxygen therapy in COPD patients with hypoxemia reduce mortality. Bronchodilators, corticosteroids, methylxanthines, phosphodiesterase-4 inhibitors, macrolide antibiotics, mucolytics, and pulmonary rehabilitation improve some outcome measures such as spirometry measures and the frequency of COPD exacerbations without improving mortality. International treatment guidelines to reduce symptoms and reduce the risk of acute exacerbations exist. Relief of dyspnea and control of anxiety are important. The approach to each patient is best individualized. Earlier use of palliative care should be considered when traditional pharmacotherapy fails to achieve outcome measures and before consideration of end-of-life issues.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23580319     DOI: 10.1007/s40266-013-0080-1

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  203 in total

Review 1.  A systematic review of the use of opioids in the management of dyspnoea.

Authors:  A-L Jennings; A N Davies; J P T Higgins; J S R Gibbs; K E Broadley
Journal:  Thorax       Date:  2002-11       Impact factor: 9.139

2.  How clinicians can help smokers to quit.

Authors:  Steven A Schroeder
Journal:  JAMA       Date:  2012-10-17       Impact factor: 56.272

3.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial.

Authors:  P S Burge; P M Calverley; P W Jones; S Spencer; J A Anderson; T K Maslen
Journal:  BMJ       Date:  2000-05-13

4.  The healthcare needs of chronic obstructive pulmonary disease patients in the last year of life.

Authors:  Helena Elkington; Patrick White; Julia Addington-Hall; Roger Higgs; Polly Edmonds
Journal:  Palliat Med       Date:  2005-09       Impact factor: 4.762

5.  Palliative care or end-of-life care in advanced chronic obstructive pulmonary disease: a prospective community survey.

Authors:  Patrick White; Suzanne White; Polly Edmonds; Marjolein Gysels; John Moxham; Paul Seed; Cathy Shipman
Journal:  Br J Gen Pract       Date:  2011-06       Impact factor: 5.386

6.  Management of drooling in disabled patients with scopolamine patches.

Authors:  Abigail Mato; Jacobo Limeres; Inmaculada Tomás; Maria Muñoz; Concepción Abuín; Javier F Feijoo; Pedro Diz
Journal:  Br J Clin Pharmacol       Date:  2010-06       Impact factor: 4.335

7.  COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program.

Authors:  Stephen Sidney; Michael Sorel; Charles P Quesenberry; Cynthia DeLuise; Stephan Lanes; Mark D Eisner
Journal:  Chest       Date:  2005-10       Impact factor: 9.410

8.  A comparison of 5-day courses of dirithromycin and azithromycin in the treatment of acute exacerbations of chronic obstructive pulmonary disease.

Authors:  Richard S Castaldo; Bartolome R Celli; Fernando Gomez; Nicole LaVallee; Joseph Souhrada; John P Hanrahan
Journal:  Clin Ther       Date:  2003-02       Impact factor: 3.393

9.  Treatment of chronic obstructive pulmonary disease with orally administered theophylline. A double-blind, controlled study.

Authors:  M R Alexander; W L Dull; J E Kasik
Journal:  JAMA       Date:  1980-11-21       Impact factor: 56.272

10.  Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency.

Authors:  R K Albert; T R Martin; S W Lewis
Journal:  Ann Intern Med       Date:  1980-06       Impact factor: 25.391

View more
  3 in total

Review 1.  Paradigms in chronic obstructive pulmonary disease: phenotypes, immunobiology, and therapy with a focus on vascular disease.

Authors:  Michael Schivo; Timothy E Albertson; Angela Haczku; Nicholas J Kenyon; Amir A Zeki; Brooks T Kuhn; Samuel Louie; Mark V Avdalovic
Journal:  J Investig Med       Date:  2017-03-03       Impact factor: 2.895

2.  Impact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare Advantage population.

Authors:  Keran Moll; Shawn X Sun; Jeffrey J Ellis; Andrew Howe; Alpesh Amin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-03-16

Review 3.  New combination treatments in the management of asthma: focus on fluticasone/vilanterol.

Authors:  Laren D Tan; Andrew L Chan; Timothy E Albertson
Journal:  J Asthma Allergy       Date:  2014-05-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.